Mezigdomide plus Velcade and dexamethasone or Kyprolis and dexamethasone showed promising response rates across multiple doses in patients with relapsed or refractory multiple myeloma, research showed ...
Cemsidomide demonstrated a 50% ORR at 100 μg, with one patient achieving a complete response and no detectable disease. The phase 1 study's dose-escalation phase is complete, and the 100 μg dose is ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — The addition of belantamab mafodotin to pomalidomide and dexamethasone improved outcomes compared with ...
A quadruplet regimen for treating transplant-ineligible, newly diagnosed multiple myeloma (MM), combining the oral drug ixazomib with daratumumab, lower-dose lenalidomide, and dexamethasone (Dara-RId) ...
Asparaginase treatment is standard in all pediatric acute lymphoblastic leukemia (ALL) regimens, whereas in adults, it is either excluded or administered for a shorter duration. Several adult ALL ...
Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A third of patients with relapsed/refractory multiple myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback